RASSF1 and cancer: In conclusion, we found that the aberrant promotor methylation of OncoMe (SHOX2, RASSF1A, SEPTIN9 and HOXA9) was a cancer-specific alteration and might be a valuable marker to aid in the differentiation of MA.